undamentalytics Newsletter
Sign in

Bolt Biotherapeutics, Inc. balance sheet

At the end of fiscal 2025, Bolt Biotherapeutics, Inc. had total assets of $56.7m, total liabilities of $30.2m and shareholders' equity of $26.5m. It held $11.7m in cash against $0 of debt: net cash of $11.7m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents62791171213
Total current assets25189173106513021
Total assets473082281601005740
Accounts payable2443211
Deferred revenue (current)2312301
Total current liabilities112123201688
Total debt0000000
Total liabilities46585647423028
Shareholders' equity−105250172113572713
Non-controlling interests and other (assets − liabilities − equity)105——————
Net debt (negative = net cash)−6−27−9−11−7−12−13
Shares outstanding————2m2m2m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: BOLT vs TRDABOLT vs OCGNBOLT vs RANI

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Bolt Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Bolt Biotherapeutics, Inc.